tafluprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
prostaglandins	4229	209860-87-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tafluprost tafluprost ophthalmic solution zioptan taflotan tapros	a prostaglandin analog is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow Molecular weight: 452.54 Formula: C25H34F2O5 CLOGP: 4.26 LIPINSKI: 0 HAC: 5 HDO: 2 TPSA: 75.99 ALOGS: -4.93 ROTB: 13 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

tafluprost
tafluprost ophthalmic solution
zioptan
taflotan
tapros

a prostaglandin analog is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow

Molecular weight: 452.54
Formula: C25H34F2O5
CLOGP: 4.26
LIPINSKI: 0
HAC: 5
HDO: 2
TPSA: 75.99
ALOGS: -4.93
ROTB: 13

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Feb. 10, 2012	FDA	OAK PHARMS INC

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ocular hyperaemia	227.61	37.09	56	871	25088	63463007
Eye irritation	159.10	37.09	41	886	21930	63466165
Eye pain	146.01	37.09	42	885	33812	63454283
Eye pruritus	116.53	37.09	31	896	18640	63469455
Eye swelling	61.51	37.09	20	907	23898	63464197
Intraocular pressure increased	42.17	37.09	11	916	6067	63482028

Showing 1 to 6 of 6 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ocular hyperaemia	87.01	57.93	21	366	11431	34945113
Eye irritation	68.46	57.93	16	371	7545	34948999

Showing 1 to 2 of 2 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ocular hyperaemia	152.53	32.39	41	1022	28165	79715160
Eye pain	89.59	32.39	29	1034	37549	79705776
Eye irritation	70.47	32.39	21	1042	20660	79722665
Eye pruritus	57.74	32.39	18	1045	20552	79722773
Pemphigoid	41.28	32.39	13	1050	15302	79728023
Atrioventricular block second degree	41.14	32.39	11	1052	7301	79736024
Cardiovascular insufficiency	34.51	32.39	8	1055	2973	79740352
Intraocular pressure increased	34.17	32.39	10	1053	9195	79734130

Showing 1 to 8 of 8 entries

Previous1Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	S01EE05	SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Prostaglandin analogues
CHEBI has role	CHEBI:66900	prostaglandin receptor agonists
FDA CS	M0017805	Prostaglandins
FDA EPC	N0000175454	Prostaglandin Analog
FDA MoA	N0000000106	Prostaglandin Receptor Agonists
FDA PE	N0000009526	Increased Prostaglandin Activity

Showing 1 to 6 of 6 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Ocular hypertension	indication	4210003	DOID:9282
Open-angle glaucoma	indication	84494001	DOID:1067

Showing 1 to 2 of 2 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.0015%	ZIOPTAN	THEA PHARMA	N202514	Feb. 10, 2012	RX	SOLUTION/DROPS	OPHTHALMIC	10864159	May 28, 2029	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Showing 1 to 1 of 1 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Prostaglandin F2-alpha receptor	GPCR	P43088	PF2R_HUMAN	AGONIST				CHEMBL	CHEMBL

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
013244	NDDF
1244607	RXNORM
187543	MMSL
1O6WQ6T7G3	UNII
26696	MMSL
4031331	VUID
4031331	VANDF
699181001	SNOMEDCT_US
704470009	SNOMEDCT_US
7451	IUPHAR_LIGAND_ID

Showing 1 to 10 of 19 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Tafluprost	HUMAN PRESCRIPTION DRUG LABEL	1	0781-6184	SOLUTION/ DROPS	0.00 mg	OPHTHALMIC	ANDA	24 sections
tafluprost	HUMAN PRESCRIPTION DRUG LABEL	1	42571-264	SOLUTION/ DROPS	0.00 mg	OPHTHALMIC	ANDA	23 sections
Tafluprost	HUMAN PRESCRIPTION DRUG LABEL	1	65302-062	SOLUTION	0.00 mg	OPHTHALMIC	ANDA	2 sections
Tafluprost Ophthalmic	HUMAN PRESCRIPTION DRUG LABEL	1	66993-429	SOLUTION/ DROPS	0.00 mg	OPHTHALMIC	NDA authorized generic	25 sections
ZIOPTAN	HUMAN PRESCRIPTION DRUG LABEL	1	17478-609	SOLUTION/ DROPS	0.00 mg	OPHTHALMIC	NDA	25 sections
ZIOPTAN	HUMAN PRESCRIPTION DRUG LABEL	1	17478-609	SOLUTION/ DROPS	0.00 mg	OPHTHALMIC	NDA	25 sections
ZIOPTAN	HUMAN PRESCRIPTION DRUG LABEL	1	17478-609	SOLUTION/ DROPS	0.00 mg	OPHTHALMIC	NDA	25 sections
ZIOPTAN	HUMAN PRESCRIPTION DRUG LABEL	1	82584-609	SOLUTION/ DROPS	0.02 mg	OPHTHALMIC	NDA	28 sections

Showing 1 to 8 of 8 entries

Previous1Next